S. Lambert-Niclot

发表

Presence of HIV-1 R5 Viruses in Cerebrospinal Fluid Even in Patients Harboring R5X4/X4 Viruses in Plasma

V. Calvez, R. Tubiana, C. Katlama, 2009, Journal of acquired immune deficiency syndromes.

The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

V. Calvez, C. Charpentier, D. Boutolleau, 2021, Journal of Infection.

Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy

V. Calvez, C. Katlama, G. Peytavin, 2010, Antimicrobial Agents and Chemotherapy.

INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels

V. Calvez, C. Katlama, A. Boyd, 2019, Open forum infectious diseases.

Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies

V. Calvez, C. Katlama, J. Izopet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.

V. Calvez, R. Tubiana, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

High level of HIV-1 resistance in patients failing long-term first-line antiretroviral therapy in Mali.

V. Calvez, O. Koita, M. Sylla, 2014, The Journal of antimicrobial chemotherapy.

Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.

V. Calvez, R. Tubiana, C. Katlama, 2014, The Journal of antimicrobial chemotherapy.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

V. Calvez, C. Charpentier, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali.

V. Calvez, R. Murphy, G. Peytavin, 2020, The Journal of antimicrobial chemotherapy.

Neutrophils in antiretroviral therapy-controlled HIV demonstrate hyperactivation associated with a specific IL-17/IL-22 environment.

G. Carcelain, R. Tubiana, B. Autran, 2014, The Journal of allergy and clinical immunology.

Determinants of a Low CD4/CD8 Ratio in HIV-1-Infected Individuals Despite Long-term Viral Suppression.

V. Calvez, G. Carcelain, R. Tubiana, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab.

A. Samri, B. Autran, J. Spano, 2017, AIDS.

HIV-1 genome is often defective in PBMCs and rectal tissues after long-term HAART as a result of APOBEC3 editing and correlates with the size of reservoirs.

V. Calvez, G. Carcelain, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.

Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs

C. Delaugerre, C. Vauloup-Fellous, A. Roque-Afonso, 2020, Journal of Clinical Microbiology.

Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing

V. Calvez, C. Charpentier, C. Katlama, 2018, The Journal of antimicrobial chemotherapy.

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002–2011 survey

V. Calvez, R. Tubiana, C. Poirot, 2012, AIDS.

Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.

V. Calvez, C. Charpentier, C. Katlama, 2015, AIDS research and human retroviruses.

Impact of Adding Enfuvirtide to the Predictive Value of the Darunavir Genotypic Resistance Score

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2011, Journal of acquired immune deficiency syndromes.

Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.

V. Calvez, C. Katlama, M. Valantin, 2011, The Journal of antimicrobial chemotherapy.

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

V. Calvez, C. Charpentier, S. Burrel, 2021, Journal of Infection.

Performance of genotypic algorithms for predicting tropism of HIV-1CRF02_AG subtype.

V. Calvez, C. Katlama, P. Girard, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma

R. Tubiana, G. Peytavin, C. Poirot, 2008, AIDS.

Effect of therapeutic intensification followed by HIV DNA prime and rAd5 boost vaccination on HIV-specific immunity and HIV reservoir (EraMune 02): a multicentre randomised clinical trial.

V. Calvez, C. Katlama, B. Autran, 2015, The lancet. HIV.

Direct Quantiﬁcation of Cell-Associated HIV DNA in Isolated Rectal and Blood Memory CD4 T Cells Revealed Their Similar and Low Infection Levels in Long-Term Treated HIV-Infected Patients

G. Carcelain, R. Tubiana, A. Samri, 2018 .

Direct Quantification of Cell-Associated HIV DNA in Isolated Rectal and Blood Memory CD4 T Cells Revealed Their Similar and Low Infection Levels in Long-Term Treated HIV-Infected Patients

G. Carcelain, R. Tubiana, A. Samri, 2013, Journal of acquired immune deficiency syndromes.

Frequency of amino acid changes associated with resistance to attachment inhibitor BMS-626529 in R5- and X4-tropic HIV-1 subtype B.

V. Calvez, C. Katlama, S. Fourati, 2013, The Journal of antimicrobial chemotherapy.

Effect of antiretroviral drugs on the quality of semen

V. Calvez, R. Tubiana, G. Peytavin, 2011, Journal of medical virology.

Evolution of the K65R, K103N and M184V/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010.

V. Calvez, C. Charpentier, D. Descamps, 2013, The Journal of antimicrobial chemotherapy.

Pharmacokinetics, protein‐binding‐adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment‐naïve HIV‐infected patients *

V. Calvez, C. Katlama, G. Peytavin, 2010, HIV medicine.

Switching to darunavir/ritonavir 800/100 mg once‐daily containing regimen maintains virological control in fully suppressed pre‐treated patients infected with HIV‐1

C. Katlama, L. Schneider, R. Murphy, 2013, Journal of medical virology.

Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa

G. Peytavin, P. Girard, L. Morand‐Joubert, 2018, The Journal of antimicrobial chemotherapy.

Transmitted drug resistance to integrase based first-line HIV antiretroviral regimens in the Mediterranean Europe.

F. Ceccherini‐Silberstein, C. Charpentier, C. Perno, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study.

C. Katlama, L. Cuzin, J. Meynard, 2012, The Journal of antimicrobial chemotherapy.

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).

A. Samri, D. Costagliola, G. Peytavin, 2016, The Journal of antimicrobial chemotherapy.

New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies.

V. Calvez, C. Katlama, J. Spano, 2020, The Journal of infectious diseases.

New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV‐1 reverse transcriptase (M184L and M184T)

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2018, Chemical biology & drug design.

Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

V. Calvez, C. Charpentier, C. Delaugerre, 2019, The Journal of antimicrobial chemotherapy.

Very early ART resulting in the absence of HIV-1 antibodies and in a sustained undetectable plasma HIV-1-RNA and proviral-DNA in an HLA-B*5701 and Δ32 heterozygote HIV-1-infected patient was not associated with functional cure.

G. Carcelain, R. Tubiana, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children

V. Calvez, C. Katlama, R. Murphy, 2023, Viruses.

Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir

V. Calvez, G. Carcelain, R. Tubiana, 2016, AIDS.

Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial

V. Calvez, B. Clotet, C. Katlama, 2016, AIDS.

Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression

V. Calvez, D. Pillay, R. Murphy, 2016, The Journal of antimicrobial chemotherapy.

Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virologic suppression

Souleymane, V. Calvez, D. Pillay, 2017 .

Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy.

V. Calvez, G. Carcelain, R. Tubiana, 2014, The Journal of antimicrobial chemotherapy.

Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases

V. Calvez, C. Katlama, N. Dupin, 2018, Journal of Clinical Microbiology.

Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V - The LAMRES Study.

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2022, Journal of global antimicrobial resistance.

Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants

V. Calvez, C. Delaugerre, C. Katlama, 2019, The Journal of antimicrobial chemotherapy.

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136

C. Katlama, B. Hoen, G. Peytavin, 2010, AIDS.

V. Calvez, C. Katlama, B. Masquelier, 2012, PloS one.

Positive Impact of HIV-1 gag Cleavage Site Mutations on the Virological Response to Darunavir Boosted with Ritonavir

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2011, Antimicrobial Agents and Chemotherapy.

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.

V. Calvez, F. Brun-Vézinet, C. Katlama, 2009, The Journal of antimicrobial chemotherapy.

Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.

H. Jessen, A. Blaxhult, V. Calvez, 2016, The Journal of antimicrobial chemotherapy.

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.

V. Calvez, C. Katlama, F. Raffi, 2016, The Journal of antimicrobial chemotherapy.

Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.

V. Calvez, C. Charpentier, B. Masquelier, 2014, The Journal of antimicrobial chemotherapy.

Factors associated with virological failure in HIV-1-infected patients receiving darunavir/ritonavir monotherapy.

V. Calvez, C. Katlama, Y. Yazdanpanah, 2011, The Journal of infectious diseases.

HIV Replication Is Not Controlled by CD8+ T Cells during the Acute Phase of the Infection in Humanized Mice

G. Marodon, A. Marcelin, S. Lambert-Niclot, 2015, PloS one.

Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study)

V. Calvez, C. Charpentier, C. Delaugerre, 2018, The Journal of antimicrobial chemotherapy.

Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression.

C. Fagard, C. Rouzioux, F. Raffi, 2016, The Journal of antimicrobial chemotherapy.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir.

V. Calvez, R. Tubiana, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.

V. Calvez, C. Charpentier, C. Katlama, 2021, The Journal of antimicrobial chemotherapy.

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.

V. Calvez, R. Tubiana, C. Katlama, 2010, The Journal of antimicrobial chemotherapy.

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

V. Calvez, R. Tubiana, C. Katlama, 2011, AIDS.

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Philippe Flandre, Vincent Calvez, Christine Katlama, 2007, Antimicrobial Agents and Chemotherapy.

New HIV-1 circulating recombinant form 94: from phylogenetic detection of a large transmission cluster to prevention in the age of geosocial-networking apps in France, 2013 to 2017

V. Calvez, P. Bellecave, D. Descamps, 2019, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.

P. Morlat, D. Costagliola, J. Alvarez, 2023, The Journal of antimicrobial chemotherapy.

Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients

V. Calvez, C. Katlama, L. Schneider, 2009, AIDS.

Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.

V. Calvez, C. Delaugerre, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.

V. Calvez, C. Charpentier, C. Delaugerre, 2012, The Journal of antimicrobial chemotherapy.

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.

V. Calvez, C. Charpentier, C. Katlama, 2015, The Journal of antimicrobial chemotherapy.

HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis

V. Calvez, R. Tubiana, C. Katlama, 2010, AIDS (London).

Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.

V. Calvez, R. Tubiana, C. Katlama, 2008, The Journal of antimicrobial chemotherapy.

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.

V. Calvez, H. Traoré, S. Fourati, 2013, The Journal of antimicrobial chemotherapy.

Description of the L76V Resistance Protease Mutation in HIV-1 B and “Non-B” Subtypes

V. Calvez, F. Ceccherini‐Silberstein, C. Charpentier, 2013, PloS one.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

V. Calvez, R. Tubiana, C. Katlama, 2008, AIDS.

Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years

V. Calvez, R. Tubiana, C. Katlama, 2011, AIDS.

SARS-CoV-2 genome quantification in wastewaters at regional and city scale allows precise monitoring of the whole outbreaks dynamics and variants spreading in the population

V. Calvez, C. Charpentier, C. Delaugerre, 2021, Science of The Total Environment.

Antiretroviral resistance at virologic failure in the NEAT 001 / ANRS 143 trial : Raltegravir + 1 Darunavir / ritonavir or Tenofovir / Emtricitabine + Darunavir / ritonavir as first line 2 antiretroviral therapy 3

H. Jessen, A. Blaxhult, V. Calvez, 2016 .

Switching to darunavir/ritonavir 800/100 mg once‐daily containing regimen maintains virological control in fully suppressed pre‐treated patients infected with HIV‐1

C. Katlama, L. Schneider, R. Murphy, 2013, Journal of medical virology.